Illumina expands MRD research portfolio with ultrasensitive sequencing technology

Compass Pathways completes FDA application for COMP360 in treatment-resistant depression

Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m

UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment

Valneva reports positive Phase 2 results for tetravalent Shigella vaccine candidate

Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease

GlycoNex submits marketing authorisation application for denosumab biosimilar to Japanese regulator

Antengene reports first patient dosed in Phase I study of ATG-201 in B cell-mediated autoimmune diseases

Akeso publishes ivonescimab Phase II study results in Nature Medicine

Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment

First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer

SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA

Circular Genomics and PharmatrophiX collaborate on advancing circRNA biomarkers in neurodegenerative drug development

Minghui Pharmaceutical licenses IGF-1R antibody to ASKA Pharmaceutical in Japan

WuXi Biologics receives two awards at 2026 HERA